Singapore, Oct. 16 -- Charles River Laboratories International, Inc. and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, have announced their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions.

The partnership will leverage Charles River's specialised expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and release testing, and extensive development support services.

By integrating Charles River's comprehensive testing and development solutions with Magellan's advances in cell therapy development, manufacturing and clinical application, the collaboration aims to drive in...